Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsWEISBERG, Ellen; HWAN GEUN CHOI; FLETCHER, Jonathan A et al.Blood. 2010, Vol 115, Num 21, pp 4206-4216, issn 0006-4971, 11 p.Article

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has In vitro activity against imatinib-resistant chronic myeloid leukemiaGOLEMOVIC, Mirna; VERSTOVSEK, Srdan; ARLINGHAUS, Ralph B et al.Clinical cancer research. 2005, Vol 11, Num 13, pp 4941-4947, issn 1078-0432, 7 p.Article

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis studyRAY, Arghya; COWAN-JACOB, Sandra W; MANLEY, Paul W et al.Blood. 2007, Vol 109, Num 11, pp 5011-5015, issn 0006-4971, 5 p.Article

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)VON BUBNOFF, Nikolas; MANLEY, Paul W; MESTAN, Jurgen et al.Blood. 2006, Vol 108, Num 4, pp 1328-1333, issn 0006-4971, 6 p.Article

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinasesMANLEY, Paul W; BREITENSTEIN, Werner; BRÜGGEN, Josef et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 23, pp 5793-5797, issn 0960-894X, 5 p.Article

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With ImatinibWHITE, Deborah L; DANG, Phuong; ENGLER, Jane et al.Journal of clinical oncology. 2010, Vol 28, Num 16, pp 2761-2767, issn 0732-183X, 7 p.Article

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL⁺ leukemiasWEISBERG, Ellen; CATLEY, Laurie; HALL-MEYERS, Elizabeth et al.Blood. 2007, Vol 109, Num 5, pp 2112-2120, issn 0006-4971, 9 p.Article

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsFISKUS, Warren; PRANPAT, Michael; ATADJA, Peter et al.Blood. 2006, Vol 108, Num 2, pp 645-652, issn 0006-4971, 8 p.Article

Synthesis and characterization of a novel tritiated K_ATP channel opener with a benzopyran structureMANLEY, Paul W; LÖFFLER-WALZ, Cornelia; RUSS, Ulrich et al.British journal of pharmacology. 2001, Vol 133, Num 2, pp 275-285, issn 0007-1188Article

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJIANMING ZHANG; ADRIAN, Francisco J; GUO, Gui-Rong et al.Nature (London). 2010, Vol 463, Num 7280, pp 501-506, issn 0028-0836, 6 p.Article

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinibj, nilotinib and dasatinibDAY, Elizabeth; WATERS, Beatrice; SPIEGEL, Katrin et al.European journal of pharmacology. 2008, Vol 599, Num 1-3, pp 44-53, issn 0014-2999, 10 p.Article

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITGLEIXNER, Karoline V; MAYERHOFER, Matthias; PICKL, Winfried F et al.Haematologica (Roma). 2007, Vol 92, Num 11, pp 1451-1459, issn 0390-6078, 9 p.Article

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity : higher doses of imatinib may overcome the negative impact of low OCT-1 activityWHITE, Deborah L; SAUNDERS, Verity A; PHUONG DANG et al.Blood. 2007, Vol 110, Num 12, pp 4064-4072, issn 0006-4971, 9 p.Article

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107) : reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibWHITE, Deborah L; SAUNDERS, Verity A; DANG, Phuong et al.Blood. 2006, Vol 108, Num 2, pp 697-704, issn 0006-4971, 8 p.Article

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinasesWARMUTH, Markus; SIMON, Nicola; MITINA, Olga et al.Blood. 2003, Vol 101, Num 2, pp 664-672, issn 0006-4971, 9 p.Article